Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Has a residual invasive cancer in the breast(non-pCR) after neoadjuvant treatment~* Has stage I, II, or III disease prior to surgery per American Joint Committee on Cancer (AJCC)~* HER 2 1+ by IHC or HER2 2+by IHC without gene amplification by ISH, as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.~* Hormone receptor (ER and PR) negative by ASCO/CAP guidelines~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Demonstrates adequate organ function.~Key Exclusion Criteria:~* Has a history of hypersensitivity or other contraindications to rhGM-CSF~* Has a history of invasive malignancy ≤5 years prior to first administration of investigational drug except for adequately treated non-melanoma skin cancer or carcinoma in situ.~* Is on immune suppression therapy or has a history of immune suppression therapy ≤4 weeks prior to the first administration of investigational drugs~* Has a history of autoimmune disease or inflammatory disease~* Has active infection including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection~* Is pregnant or breastfeeding or expecting to conceive children

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AST-301(pNGVL3-hICD)+Chemotherapy (Type: EXPERIMENTAL): * AST-301/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy\*~* A booster (AST-301/rhuGM-CSF) at 24 weeks post the third vaccination~  * Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)
- Placebo + Chemotherapy (Type: ACTIVE_COMPARATOR): * Placebo/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy\*~* A booster (Placebo/rhuGM CSF) at 24 weeks post the third vaccination~  * Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).